Uit onderzoek van Pfizer blijkt er mogelijk eenrelatie te zijn tussen het inhalatie insuline Exubera en lngkanker. Pfizer stopt met de marketing van Exubera.
The Wall Street Journal (4/10, D2, Johnson) reports that “Pfizer, Inc. said [on] Wednesday that during clinical trials, six” patients “taking its inhaled insulin, Exubera (insulin human [rDNA origin]), developed lung cancer, compared with one case of the malignancy among patients not using Exubera.” Last October, Pfizer said that it would “stop marketing the medicine, citing lackluster demand.” Still, the drug “has remained available while doctors transitioned patients to new therapies, and Pfizer’s partner, Nektar Therapeutics of San Carlos, Calif., sought a new marketing partner.”
